Trial Profile
The utility of genomics and functional imaging to predict Sunitinib pharmacokinetics and pharmacodynamics: The PREDICT SU Study
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 02 Jul 2019
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours; Renal cell carcinoma
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
- Acronyms PREDICT-SU
- 30 Jun 2018 Status changed from active, no longer recruiting to discontinued.
- 05 Jun 2018 Results (n=15) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 24 Jun 2016 Status changed from not yet recruiting to active, no longer recruiting.